It is made available under a CC-BY-NC 4.0 International license .

- Fixed-Dose Combination Use and Drug Adherence, Healthcare Utilization, and Costs 1 2 Donglan Zhang, PhD<sup>1,2,\*</sup>, Jun Soo Lee, PhD<sup>3,\*</sup>, Nicole L. Therrien, PharmD, MPH<sup>3</sup>, 3 Lisa M. Pollack, PhD, MPH, MPT<sup>3</sup>, Sandra L. Jackson, PhD, MPH<sup>3</sup>, Xiaobei Dong, PhD<sup>4</sup>, Anand Rajan, MS,<sup>1</sup> Kai Hong, PhD,<sup>5</sup> Andrew E. Moran, MD, MPH,<sup>6</sup> and Feijun Luo, PhD<sup>3</sup> 4 5 6 7 \* Donglan Zhang and Jun Soo Lee are joint 1st authors with equal contributions. 8 9 Author Affiliations: <sup>1</sup> Center for Population Health and Health Services Research, Department of Foundations of 10 11 Medicine, New York University Grossman Long Island School of Medicine, Mineola, NY <sup>2</sup> Department of Population Health, New York University Grossman School of Medicine, New 12 York. NY 13 <sup>3</sup> Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, 14 Atlanta, GA 15 <sup>4</sup> Joseph J. Zilber College of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI 16 <sup>5</sup> Policy Analysis and Engagement Office, Office of Policy, Performance, and Evaluation, 17 Centers for Disease Control and Prevention, Atlanta, GA 18 <sup>6</sup> Division of General Medicine, Columbia University Irving Medical Center 19 20 21 **Correspondence to:** Feijun Luo, PhD 22 23 Economist 24 Division for Heart Disease and Stroke Prevention Centers for Disease Control and Prevention 25 26 Phone: 770-488-3896 Email: hto1@cdc.gov 27 28 29 Word count: abstract: 341; main text: 3,492 Number of tables/figures 5; references: 41 30 31 Conflict of Interest Disclosures: None 32 33 Funding: None 34 35 Disclaimer: The findings and conclusions in this report are those of the authors and do not 36 necessarily represent the official position of the Centers for Disease Control and Prevention. Use 37 of trade names and commercial sources is for identification only and does not imply endorsement 38 by the U.S. Department of Health and Human Services. 39 40
- 41 Acknowledgments: The authors are genuinely grateful to Michael Schooley (Centers for Disease
- 42 Control and Prevention) for their guidance, suggestions, and article review.

It is made available under a CC-BY-NC 4.0 International license .

#### 43 Abstract

- 44 **BACKGROUND:** Combination-pill therapy using fixed-dose combination (FDC)
- 45 antihypertensives has the potential to improve hypertension control and management. However,
- 46 combination-pill therapy remains low. This study aims to assess 1) the association between
- 47 combination-pill therapy and subsequent medication adherence, healthcare utilization, and costs
- and 2) the potential to mitigate racial and ethnic disparities in medication adherence, among
- 49 Medicaid beneficiaries.
- 50 **METHODS:** A retrospective cohort analysis was conducted using the 2017-2021 Merative<sup>TM</sup>
- 51 MarketScan® Medicaid claims database. The study sample included adults aged 18-64 years
- 52 with hypertension, continuously enrolled one year before and after a random index date of
- 53 prescribed antihypertensives. Combination-pill therapy was compared with multi-pill therapy.
- 54 The propensity-score overlap weighting method was used to balance characteristics between
- 55 individuals using combination- and multi-pill therapy. Logistic models were used for medication
- adherence, linear models for medication possession ratios (MPRs), negative binomial models for
- 57 healthcare utilization, and generalized linear models for healthcare costs.
- 58 **RESULTS:** Compared with multi-pill therapy, combination-pill therapy was associated with
- improved medication adherence (3.17 in MPR, 95% CI: 2.79 3.55), fewer hypertension-related
- 60 emergency department visits (220 per 1,000 individuals, 95% CI: -235 -204), fewer
- hospitalizations (153 per 1,000 individuals, 95% CI: -160 -146), and lower medical costs
- 62 (\$2,862 per person, 95% CI: -\$3,035 -\$2,689). However, disparities in medication adherence
- between non-Hispanic White and non-Hispanic Black adults existed for both FDC and multi-pill
- 64 therapy.
- 65 **CONCLUSIONS:** Combination-pill therapy could improve hypertension management and save
- 66 costs for the Medicaid program and beneficiaries. These findings may inform policies on FDC
- 67 antihypertensive coverage and programs.

It is made available under a CC-BY-NC 4.0 International license .

### 68 Introduction

Hypertension is a major risk factor for cardiovascular disease, stroke, kidney disease, and
dementia,<sup>1-3</sup> affecting about half of Americans based on the 2017 American College of
Cardiology and American Heart Association (ACC/AHA) definition for hypertension (threshold:
130/80 mmHg).<sup>4</sup> Non-Hispanic Black (NHB) adults have substantially higher hypertension
prevalence but lower medication adherence and prevalence of blood pressure control than NonHispanic White (NHW) and Hispanic adults.<sup>5,6</sup>

75 Fixed-dose combination (FDC) therapy that combines  $\geq 2$  antihypertensive medications into a 76 single pill (a treatment strategy referred to as combination-pill therapy in this study) simplifies medication regimens and has been proven safe and effective.<sup>7</sup> Combination-pill therapy using 77 FDC antihypertensives may improve medication adherence and hypertension control.<sup>8</sup> The 2017 78 79 ACC/AHA guideline recommended lower blood pressure thresholds and using combination-pill antihypertensive therapy as an initial management strategy for some individuals to control 80 hypertension more quickly and effectively.<sup>9</sup> The 2018 European Society of Cardiology/European 81 82 Society of Hypertension and the Japanese Society of Hypertension guidelines also highlighted the importance of FDC-antihypertensives for hypertension treatment and recommend initial 83 combination-pill therapy in almost all patients.<sup>10</sup> 84

<sup>85</sup>Despite the promise of combination-pill therapy, its utilization for hypertension treatment in <sup>86</sup>the United States remains low.<sup>11,12</sup> This could be due to several reasons. One is that certain FDC-<sup>87</sup>antihypertensives, although approved, may not be included in health care systems' treatment <sup>88</sup>protocols and insurance coverage formularies.<sup>13,14</sup> Therapeutic inertia may also play a role, and <sup>89</sup>there are concerns among health care professionals regarding the safety and efficacy, availability <sup>90</sup>of different combinations, insurance coverage, and access to detailed FDC-antihypertensive

3

It is made available under a CC-BY-NC 4.0 International license .

91 information.<sup>15</sup> These barriers may particularly affect low-income and racial and ethnic minority

92 populations, who may disproportionately face financial burden if insurance does not cover these

93 drugs.<sup>16,17</sup> Evidence is lacking regarding whether combination-pill therapy is effective in

- 94 mitigating racial and ethnic disparities in hypertension management.
- 95 To address this evidence gap, using large-scale claims data, we conducted an analysis among

96 Medicaid beneficiaries to investigate: 1) the association between combination-pill therapy and

97 subsequent medication adherence, healthcare utilization and medical expenses over a one-year

period, and 2) whether the associations between combination-pill therapy and hypertension-

99 related outcomes vary across racial and ethnic groups.

It is made available under a CC-BY-NC 4.0 International license .

#### 100 Methods

#### 101 Data Sources and Study Population

Data were obtained from the Merative<sup>TM</sup> MarketScan<sup>®</sup> multistate Medicaid claims database 102 from 2016 to 2022. To build our study sample (Appendix Figure 1), we first identified 103 104 Medicaid beneficiaries who had  $\geq 1$  hypertension diagnosis (ICD-10-CM codes I10-I15) and had ≥1 pharmacy claims for an antihypertensive medication between January 2017 and December 105 2021 (study period, Appendix Table 1). During this period, we selected a random date as the 106 index date to define the time when individuals filled or refilled antihypertensive medications. 107 The random selection of the index date is preferred over identifying an index date based on the 108 order of a pharmacy claim, as the latter would oversample individuals from earlier years 109 compared with later years.<sup>18</sup> A random index date allows for a more even distribution of 110 individuals who initiated medications at different times across the study period and has been 111 widely used in claims data analysis.<sup>18,19</sup> We then restricted the sample to those who (1) were 112 aged 18-64 years at the index date, (2) were continuously enrolled in one Medicaid insurance 113 plan for the entire 1-year follow-up period post-index date, (3) had one year of data for 114 prescribed antihypertensives before and after the index date. 115

We excluded beneficiaries aged ≥65 years who may have been dually eligible for Medicare, as well as those who had a pregnancy diagnosis during the study period, as pregnancy may affect medication regimens.<sup>20</sup> In addition, to streamline the comparison between those using combination-pill therapy and those using non-FDC-antihypertensives for two different medication classes (referred to as multi-pill therapy in this study), we excluded beneficiaries who switched between combination-pill therapy and multi-pill therapy. We also excluded those who

It is made available under a CC-BY-NC 4.0 International license .

used only one antihypertensive therapeutic class to create comparable groups for the two therapy types. Finally, when calculating the annual healthcare costs, we identified a subset of adults not covered by capitated health insurance plans because fixed annual payment model plans do not fully reflect healthcare costs incurred when receiving services.<sup>21</sup>

#### 126 Outcomes

The primary outcomes of the study included 1) antihypertensive medication adherence within 127 one year post-index date, 2) emergency department (ED) visits and inpatient admissions 128 associated with hypertension and cardiovascular disease (CVD) per 1,000 individuals within 129 one-year post-index date, and 3) hypertension-related medical costs (overall, and separately for 130 ED visits and inpatient admissions) within one year post-index date and 4) CVD-related medical 131 132 costs (overall, and separately for ED visits and inpatient admissions) within one year post-index date. Sensitivity analyses examined all-cause costs. Hypertension-related and CVD-related 133 healthcare utilization and total medical costs were defined based on the presence of the 134 respective diagnosis codes (hypertension: ICD-10-CM codes I10-I15; CVD: ICD-10-CM codes 135 I00-I78).<sup>22</sup> 136

Medication adherence was measured using the medication possession ratio (MPR), with MPR 137  $\geq$ 80% indicating adequate adherence to antihypertensive medications.<sup>23,24</sup> The average MPR was 138 computed as the ratio of the total days of antihypertensive drug supply to the number of days in 139 each vear.<sup>23</sup> For combination-pill therapy, we derived the average MPRs for all available FDC-140 antihypertensives in the database (Appendix Table 2) and for the seven antihypertensive 141 therapeutic classes including Angiotensin-Converting Enzyme (ACE) inhibitors, angiotensin 142 143 receptor blockers (ARB), beta-blockers, calcium channel blockers (CCB), diuretics, other antihypertensives, and renin-angiotensin system antagonists separately, along with the 144

medRxiv preprint doi: https://doi.org/10.1101/2024.11.27.24318118; this version posted November 29, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

145 corresponding generic drug names.<sup>24</sup> For multi-pill therapy, we derived the average MPRs for
146 each antihypertensive medication.

For our secondary outcomes, we assessed 1) Medicaid insurance payments (including all
adjusted payments for healthcare services from the Medicaid program), 2) patient out-of-pocket
(OOP) costs (including copay, coinsurance and deductibles) and 3) total costs (the sum of the
Medicaid insurance payments and patient OOP costs for combination-and multi-pill therapy per
individual. All secondary outcomes reflect results within one-year post-index date.
All outcomes were stratified by race and ethnicity (NHW, NHB, and Hispanic populations).
We did not stratify by other racial groups due to their high heterogeneity.

#### 154 Exposure

- 155 Combination-pill therapy was defined as having a pharmacy claim for ≥1 FDC-
- antihypertensive medication and no other antihypertensive medications from the index date
- through the follow-up period. The comparison was multi-pill therapy, defined as having no
- 158 claims for FDC-antihypertensives but having claims for ≥2 different antihypertensive medication

159 classes from the index date through the follow-up period.

#### 160 Statistical Analysis

We used propensity score (PS) overlap weighting methods to balance characteristics between individuals using combination- and multi-pill therapy (**Appendix Figure 2**).<sup>25,26</sup> In calculating the PS, we included age groups (18-34, 35-44, 45-54, and 55-64 years), gender, race and ethnicity (NHW, NHB, Hispanic, and other racial groups), dummy indicators for risk factors (alcohol use, tobacco use, obesity, and lipid disorders), and 12 comorbidities identified in the Charlson comorbidity index (CCI, excluding myocardial infarction, congestive heart failure,

It is made available under a CC-BY-NC 4.0 International license .

peripheral vascular disease, cerebrovascular disease, and renal disease from the original CCI
because these comorbidities may be in the causal pathways between antihypertensive medication
use and CVD outcomes).<sup>27</sup>. All sociodemographic and comorbidity variables were measured in
the one-year period prior to the index date.

We employed logistic models for medication adherence and linear models for MPRs. We then 171 172 employed negative binomial models to estimate all healthcare utilization outcomes. We utilized generalized linear models with gamma distribution and log link function to accommodate the 173 skewed distribution of healthcare costs.<sup>28</sup> In sensitivity analyses, we included those who used 174 both combination-pill and multi-pill therapy in the same year (to create a more inclusive 175 definition of the combination-pill therapy group, allowing for inclusion in the exposure group of 176 patients who may have switched between regimens or who may have been taking an FDC-177 antihypertensive along with additional antihypertensive agents simultaneously) and tested the 178 robustness of the results. 179

All models were additionally adjusted for fixed effects for the year and month of the index date to control for time-invariant fixed effects within a year or a month. In each model, we compared outcomes between combination-and multi-pill therapy groups within the entire population, as well as within each race and ethnicity. We tested whether outcomes between combination- and multi-pill therapy groups differed by race/ethnicity by examining the statistical significance of interaction terms between therapy type and race/ethnicity.

Average marginal effects and corresponding 95% confidence intervals (95% CI) were reported. Sensitivity analyses were conducted to assess the association between combination-pill therapy and all-cause healthcare utilization, as combination-pill therapy may have spillover effects on other disease outcomes and related healthcare utilization. All analyses were conducted

8

It is made available under a CC-BY-NC 4.0 International license .

- using Stata SE 17.0 statistical software (StataCorp, College Station, TX) and SAS version 9.4
- 191 (SAS 9.4, Cary, NC. SAS Institute Inc.).

It is made available under a CC-BY-NC 4.0 International license .

#### 192 **Results**

After sample selection, a total of 325,600 adults with Medicaid coverage were included in the analysis of healthcare utilization outcomes. In the subset analysis among those not covered by capitated insurance, 128,528 adults were included in the assessment of cost outcomes (**Appendix Figure 1**).

#### **197** Sample Characteristics

Among 325,600 adults, 29,328 (9%) used combination-pill therapy to manage their

hypertension, while 296,272 (91%) used multi-pill therapy (**Table 1**). Compared with the multi-

pill therapy group, the combination-pill therapy group was significantly younger (48.2 vs. 49.4,

p<0.001) and had a higher proportion of females (64.11% vs. 55.01%, p<0.001) and NHB adults

202 (33.12% vs. 28.15%, p<0.001). The combination-pill therapy group also had a lower proportion

of alcohol and tobacco use (both p<0.001) and a lower proportion of some comorbidities

204 (dementia, chronic pulmonary disease, rheumatic disease and diabetes), but higher proportion of

others (obesity, diabetes, and lipid disorders) (all p<0.001). After weighting the sample using the

206 PS overlap approach, the characteristics between individuals using combination-pill and multi-

207 pill therapy were not statistically significant (**Appendix Figure 2**).

#### 208 Association between Combination-Pill Therapy and Medication Adherence

209 After PS overlap weighting, compared with multi-pill therapy, combination-pill therapy was

associated with, on average, an 8.5 percentage point (95% CI: 7.9 - 9.1) higher likelihood of

- medication adherence (MPR  $\ge$  80%) or 3.17 (95% CI: 2.79 3.55) higher average MPR (**Table**
- 212 2). The associations were strongest among NHW adults, who had a 9.7 percentage point (95%
- CI: 8.9 10.5) higher likelihood of medication adherence when using combination-pill vs multi-

It is made available under a CC-BY-NC 4.0 International license .

214	pill therapy, compared with the 6.9 percentage point (95% CI: $5.9 - 7.9$ ) higher likelihood
215	among NHB and 5.7 percentage point (95% CI: 2.9 – 8.5) among Hispanic adults (p<0.001).
216	Association between Combination-Pill Therapy and Healthcare Utilization and Costs
217	Compared with multi-pill therapy, those using combination-pill therapy experienced, on
218	average, 220 fewer hypertension-related ED visits (95% CI: -235204), 153 fewer
219	hypertension-related inpatient admissions (95% CI: -160146), 270 fewer CVD-related ED
220	visits (95% CI: -287 – -254), and 181 fewer CVD-related inpatient admissions (95% CI: -189 – -
221	173) per 1,000 individuals one year after the index date (Table 3). These effects were most
222	pronounced among NHB adults. Compared with multi-pill therapy, combination-pill therapy use
223	among NHB adults was associated with reductions of 287 (95% CI: -318256) hypertension-
224	related ED visits, 192 (95% CI: -204180) hypertension-related inpatient visits, 337 (95% CI: -
225	368305) CVD-related ED visits, and 215 (95% CI: -228202) CVD-related inpatient visits
226	per 1,000 individuals one year after the index date. Among NHW adults, combination-pill
227	therapy was associated with reductions of 172 (95% CI: -192152) hypertension-related ED
228	visits, 134 (95% CI: -142125) hypertension-related inpatient visits, 225 (95% CI: -246
229	204) CVD-related ED visits, and 167 (95% CI: -177158) CVD-related inpatient visits per
230	1,000 individuals one year after the index date. Combination-pill therapy was associated with the
231	least reduction in ED and inpatient visits among Hispanic adults.
232	Among those with non-capitated Medicaid plans, compared with multi-pill therapy,
233	combination-pill therapy was associated with a \$2,862 per-person reduction in total
234	hypertension-related medical costs one year after the index date (95% CI: -\$3,035\$2,689),
235	including \$225 (95% CI: -\$251 – -\$199) for hypertension-related ED visits and \$2,280 (95% CI:
236	-\$2,464 – -\$2,096) for hypertension-related inpatient admissions ( <b>Table 4</b> ). Combination-pill

It is made available under a CC-BY-NC 4.0 International license .

237	therapy was also associated with a reduction of total CVD-related medical costs by \$3,779 per
238	person (95% CI: -\$3,978\$3,581), with reductions of \$269 (95% CI: -\$295\$242) for CVD-
239	related ED visits and \$2,798 (95% CI: -\$3,018\$2,578) for CVD-related inpatient visits.
240	Among NHB adults, combination-pill therapy was associated with a reduction of hypertension-
241	related medical costs by \$3,896 per-person (95% CI: -\$4,198\$3,595), compared with \$2,126
242	(95% CI: -\$2,339\$1,912) for NHW adults and \$1,259 (95% CI: -\$1,584\$934) for Hispanic
243	adults (P<0.001). In addition, combination-pill therapy was associated with a reduction of CVD-
244	related medical costs by \$4,914 per-person (95% CI: -\$5,258\$4,571) among NHB adults,
245	compared with \$3,012 (95% CI: -\$3,255\$2,769) for NHW adults and \$1,727 (95% CI: -

246 \$2,095 – -\$1,359) for Hispanic adults (p<0.001).

#### 247 Sensitivity Analyses

In sensitivity analyses, compared with multi-pill therapy, combination-pill therapy was
associated with a significant reduction in all-cause healthcare utilization and medical costs one
year after the index date, with a stronger association observed among NHB adults (p<0.001,</li> **Appendix Table 3 and 4**). Further, 82,126 (22%) used both combination- and multi-pill therapy
during the same year, (**Appendix Table 5**). Including individuals who used both therapies did
not alter the findings or conclusions (**Appendix Figure 3, Appendix Table 6-9**).

# Comparison of Annual and Out-Of-Pocket Costs between Combination-and Multi-Pill Therapy groups

The annual per-person costs for combination-pill therapy (\$111 95% CI: \$107 – \$115) were significantly lower than those for multi-pill therapy (\$273, 95% CI: \$270 – \$275). The patient OOP costs for combination-pill therapy (\$8) were also lower than those for multi-pill therapy

It is made available under a CC-BY-NC 4.0 International license .

- 259 (\$13) (P<0.001) (Figure 1). However, among those who used combination-pill therapy, NHB
- beneficiaries had similar annual medication costs (\$110) to NHW (\$107) but significantly higher
- than Hispanic adults (\$61).

It is made available under a CC-BY-NC 4.0 International license .

#### Discussion 262

263	In this cohort study of Medicaid beneficiaries with hypertension, we found that 9% used
264	combination-pill therapy to manage their blood pressure. Combination-pill therapy was
265	significantly associated with higher medication adherence, fewer ED visits and hospitalizations,
266	and lower medical costs compared with multi-pill therapy. Combination-pill therapy was also
267	associated with lower Medicaid payments and patient OOP costs than multi-pill therapy.
268	However, improvement in medication adherence was smaller among NHB adults than NHW
269	adults for combination-pill therapy versus multi-pill therapy, but NHB adults showed a more
270	pronounced association with reduced healthcare utilization and costs.
271	Compared with the reported prevalence of FDC-antihypertensive/combination-pill therapy
272	among all U.S. adults with hypertension based on National Health and Nutrition Examination
273	Survey (NHANES) 2017-March 2020 (27.8%), <sup>9</sup> we found a lower prevalence of Medicaid
274	beneficiaries using FDC-antihypertensives exclusively (9%, our main analysis definition of
275	combination-pill therapy) or using a mix of FDC-antihypertensives and other antihypertensives
276	during the same year (22%; our more inclusive sensitivity analysis definition of combination-pill
277	therapy) between 2017-2021. Previous reports indicated a decrease in FDC-antihypertensive use
278	from 2012 to 2020, <sup>9</sup> with Medicare and Medicaid FDC claims decreasing from 2016 to 2020. <sup>29</sup>
279	The majority of FDC-antihypertensives are available in generic form, <sup>29</sup> and our analysis showed
280	that Medicaid payments and patient OOP costs were lower for combination-pill therapy. Given
281	the small proportion of Medicaid beneficiaries with hypertension using combination-pill therapy,
282	barriers to use of combination-pill therapy may not be attributed to costs. Prior work has
283	documented barriers including lack of sufficiently diverse FDC-antihypertensive therapeutic
284	options with respect to medication classes and dosage; one study estimated that nearly two-thirds

It is made available under a CC-BY-NC 4.0 International license .

of US adults with hypertension were using a regimen not available as an FDC-antihypertensive
 product.<sup>11</sup>

Consistent with the literature,<sup>30,31</sup> our analysis demonstrated that combination-pill therapy was 287 288 associated with significantly higher medication adherence. However, combination-pill therapy was less associated with medication adherence in NHB adults (1.76, 95% CI: 1.09 - 2.44) 289 290 compared with NHW adults (3.88, 95% CI: 3.34 - 4.42). This finding may be attributable to 291 several reasons. First, the majority of FDC-antihypertensives were combinations of ACE inhibitors or ARBs plus thiazide diuretics,<sup>29</sup> and ACE inhibitors and ARBs may be insufficient 292 293 for improving hypertension control for NHB adults, possibly due to poorer medication adherence and/or differences in physiological pathways.<sup>32-34</sup> The AHA/ACC guideline recommends initial 294 antihypertensive treatment with a thiazide diuretic or CCBs for NHB adults. However, there are 295 no CCB/thiazide diuretic FDC-antihypertensives, which represents a gap for guideline-296 recommended combination-pill therapy for NHB adults, who may have a less robust response to 297 ACEIs, ARBs, and beta-blockers.<sup>35</sup> Second, there may be differences in plan enrollment and 298 coverage formularies at the state or plan level, particularly in states with managed care 299 organizations. As shown in our analysis, there were some slight variations in costs for NHB 300 301 beneficiaries compared with NHW and Hispanic beneficiaries. NHB beneficiaries may be more likely to be enrolled in plans with higher cost-sharing responsibilities compared with NHW and 302 Hispanic Medicaid beneficiaries.<sup>36</sup> However, our data did not include data on insurance benefit 303 designs, so this is beyond the scope of the present analysis and may be investigated in national 304 Medicaid claims databases in the future. 305

We observed that combination-pill therapy was associated with greater reductions in ED andinpatient visits among NHB adults compared with NHW adults, despite a smaller association

15

It is made available under a CC-BY-NC 4.0 International license .

with medication adherence. This could be because NHB adults initially had much lower 308 medication adherence and higher healthcare utilization and costs. Thus, they might benefit more 309 from using combination-pill therapy. If NHB adults had medication adherence comparable to 310 311 NHW adults, the reduction in healthcare utilization and costs might have been even larger. In contrast, Hispanic adults had higher medication adherence than NHB adults initially, but the 312 313 lowest healthcare utilization and costs. Previous studies have reported that Hispanic adults are less likely to seek health care due to language, cultural barriers, and immigration status.<sup>37</sup> This 314 315 could partially explain why the associations between combination-pill therapy and lower 316 healthcare utilization and costs were smaller among Hispanic adults compared with NHW adults. Our study has important implications. While combination-pill therapy has the potential to 317 improve medication adherence, the available options in the US may not offer the variety of class 318 and dose combinations preferred by clinicians. An analysis of 2015-2020 NHANES data found 319 189 unique therapeutic class combination regimens among US adults using antihypertensives, 320 only 7 of which (3.7%) were available as FDC-antihypertensives.<sup>11</sup> Similar findings are seen 321 among combination regimens in the Systolic Blood Pressure Intervention Trial (SPRINT).<sup>11,38</sup> 322 There are no available combinations containing four antihypertensives, which were used by over 323 324 25% of SPRINT participants. The availability of only two- or three-drug FDC-antihypertensives, and no four- or five-drug FDC-antihypertensives, limits the treatment options for patients in the 325 U.S. who require multiple antihypertensives to achieve hypertension control.<sup>39</sup> Furthermore, the 326 327 need for triple and quadruple drug combinations may increase because ACC/AHA hypertension treatment guidelines have recommended more intensive treatment goals (lower target blood 328 pressures).<sup>40</sup> Factors such as drug shortages, changes in insurance coverage or cost-sharing tiers, 329 or concerns about side effects may deter initiation or prompt switching from FDC-330

16

antihypertensives to other antihypertensives. Moreover, while 90% of Medicaid plans cover at
least four FDC-antihypertensives, and 100% cover at least one FDC-antihypertensive, individual
drug coverage and costs vary by state Medicaid programs.<sup>39</sup> Some drugs are on preferred (Tier 1)
or non-preferred (Tier 2) tiers, which may influence clinicians' prescribing behavior. To address
these gaps, policymakers and pharmaceutical companies could consider exploring and
broadening FDC-antihypertensive options with a wider range of drug class combinations to suit
the variety of treatment needs faced by prescribing clinicians.<sup>41</sup>

#### 338 Limitations

We acknowledge several limitations. First, we only tracked short-term outcomes over a single 339 year of combination-pill therapy use, leaving the long-term impacts of combination-pill therapy, 340 341 such as mortality and productivity, unknown. Second, as we used a multistate Medicaid claims database, our findings may not be generalizable to individuals covered by other types of 342 insurance, particularly because the price of FDC-antihypertensives covered by Medicaid tends to 343 be lower than that of equivalent drugs covered by Medicare and private insurance.<sup>29</sup> 344 Additionally, individual drug coverage and costs vary by state Medicaid programs, which may 345 lead to disparities in access and treatment patterns across different states. However, our data do 346 not include state identifiers, preventing us from differentiating Medicaid medication coverage 347 policies or decisions at the state level. Third, our claims database only shows whether 348 349 prescriptions were filled and picked up, not if patients actually took the medications. In addition, 350 we could not analyze data at the prescribing clinician level, accounting for variance due to 351 clinician behavior. These issues may lead to potentially overestimation of medication adherence. 352 Fourth, our main analysis focused on individuals exclusively using combination-pill therapy (excluding those who used both combination-pill therapy and other antihypertensives in a single 353

It is made available under a CC-BY-NC 4.0 International license .

year), which may limit generalizability. However, our sensitivity analyses included individuals

355 who used both combination- and multi-pill therapy in the same year, and results were consistent

356 with the main findings. Finally, we could not ascertain the doses of FDC-antihypertensives,

357 which may affect the healthcare utilization outcomes we assessed.

### 358 **Conclusions**

359 This large-scale study among Medicaid beneficiaries in multiple states (5 to 8 states from year

to year) across the US found that combination-pill therapy was associated with higher

361 medication adherence, lower healthcare utilization, and lower healthcare costs for the Medicaid

362 program and beneficiaries. However, the magnitude of these associations differs by racial and

363 ethnic groups. These research findings may help inform policies related to FDC-antihypertensive

364 medication coverage or formulary decisions, as well as programs aimed at improving medication

adherence and hypertension control. In addition, our findings can provide important evidence for

366 clinicians when selecting antihypertensive medications for patients.

#### 367 **References**

1. Kokubo Y, Iwashima Y. Higher blood pressure as a risk factor for diseases other than stroke and ischemic heart disease. *Hypertension*. 2015;66(2):254-259.

Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. *Hypertension*.
 2020;75(2):285-292.

372 3. Burnier M, Damianaki A. Hypertension as cardiovascular risk factor in chronic kidney 373 disease. *Circulation research*. 2023;132(8):1050-1063.

Carey RM, Whelton PK, Committee\* AAHGW. Prevention, detection, evaluation, and
 management of high blood pressure in adults: synopsis of the 2017 American College of
 Cardiology/American Heart Association Hypertension Guideline. *Annals of internal medicine*.

377 2018;168(5):351-358.

5. Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. 2020;

Aggarwal R, Chiu N, Wadhera RK, et al. Racial/ethnic disparities in hypertension
 prevalence, awareness, treatment, and control in the United States, 2013 to 2018.

382 *Hypertension*. 2021;78(6):1719-1726.

383 7. Salam A, Huffman MD, Kanukula R, et al. Two - drug fixed - dose combinations of blood
 384 pressure - lowering drugs as WHO essential medicines: an overview of efficacy, safety, and
 385 aset. The lowered of Clinical Hypertension, 2020;22(10):1760, 1770.

cost. *The Journal of Clinical Hypertension*. 2020;22(10):1769-1779.

Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on
 adherence to prescription medications. *Journal of general internal medicine*. 2008;23:611-614.

Mobley CM, Bryan AS, Moran AE, Derington CG, Zhang Y, Bellows BK. Fixed - dose
 combination medication use among US adults with hypertension: a missed opportunity. *Journal* of the American Heart Association. 2023;12(4):e027486.

Mahfoud F, Kieble M, Enners S, et al. Use of fixed-dose combination antihypertensives
in Germany between 2016 and 2020: an example of guideline inertia. *Clinical Research in Cardiology*. 2023;112(2):197-202.

11. Derington CG, Bress AP, Herrick JS, et al. Antihypertensive medication regimens used
by US adults with hypertension and the potential for fixed - dose combination products: the
national health and nutrition examination surveys 2015 to 2020. *Journal of the American Heart Association*. 2023;12(11):e028573.

Berington CG, King JB, Herrick JS, et al. Trends in antihypertensive medication
 monotherapy and combination use among US adults, National Health and Nutrition Examination
 Survey 2005–2016. *Hypertension*. 2020;75(4):973-981.

13. DiPette DJ, Skeete J, Ridley E, et al. Fixed - dose combination pharmacologic therapy
to improve hypertension control worldwide: clinical perspective and policy implications. *The Journal of Clinical Hypertension*. 2019;21(1):4.

404 14. Esba LCA, Yousef C, Ismail S, et al. Fixed dose combinations: a formulary decision
405 guide. *Health Policy and Technology*. 2021;10(2):100500.

406 15. DiPette DJ, Goughnour K, Zuniga E, et al. Standardized treatment to improve

hypertension control in primary health care: The HEARTS in the Americas Initiative. *The Journal* of *Clinical Hypertension*. 2020;22(12):2285-2295.

409 16. Kogut SJ. Racial disparities in medication use: imperatives for managed care pharmacy.
410 *Journal of managed care & specialty pharmacy*. 2020;26(11):1468-1474.

411 17. Fiscella K, Sanders MR. Racial and ethnic disparities in the quality of health care.

Annual review of public health. 2016;37:375-394.

18. Bødkergaard K, Selmer RM, Hallas J, et al. Using the waiting time distribution with

random index dates to estimate prescription durations in the presence of seasonal stockpiling.

415 *Pharmacoepidemiology and Drug Safety*. 2020;29(9):1072-1078.

416 19. Klungel OH, Heckbert SR, Longstreth Jr W, et al. Antihypertensive drug therapies and the risk of ischemic stroke. Archives of internal medicine. 2001;161(1):37-43. 417 418 20. Chandrasekaran S, Badell ML, Jamieson DJ. Management of chronic hypertension 419 during pregnancy. JAMA. 2022;327(17):1700-1701. 420 Holahan J, Suzuki S. Medicaid managed care payment methods and capitation rates in 21. 421 2001. Health Affairs. 2003;22(1):204-218. Lee JS, Bhatt A, Pollack LM, et al. Racial and Ethnic Differences in Hypertension-422 22. 423 Related Telehealth and In-Person Outpatient Visits Before and During the COVID-19 Pandemic 424 Among Medicaid Beneficiaries. Telemedicine and e-Health. 2024; 425 Canfield SL, Zuckerman A, Anguiano RH, et al. Navigating the wild west of medication 23. 426 adherence reporting in specialty pharmacy. Journal of managed care & specialty pharmacy. 427 2019;25(10):1073-1077. 428 Lee JS, Segura Escano R, Therrien NL, et al. Antihypertensive Medication Adherence 24. 429 and Medical Costs, Health Care Utilization, and Labor Productivity among Persons with Hypertension. medRxiv. 2024:2024.04. 15.24305866. 430 Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that 431 25. 432 mimics attributes of a randomized clinical trial. Jama. 2020;323(23):2417-2418. 433 Li F. Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. 26. 434 American journal of epidemiology. 2019;188(1):250-257. 435 27. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. Journal of clinical 436 437 epidemiology. 2004;57(12):1288-1294. 438 28. Deb P, Trivedi PK. The structure of demand for health care: latent class versus two-part 439 models. Journal of health economics. 2002;21(4):601-625. 440 29. Essa M, Ross JS, Dhruva SS, Desai NR, Spatz ES, Faridi KF. Utilization of Fixed-Dose 441 Combination Treatment for Hypertension in Medicare and Medicaid From 2016 to 2020. 442 Circulation: Cardiovascular Quality and Outcomes. 2024;17(5):e010697. 443 Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations 30. 444 improve medication compliance: a meta-analysis. The American journal of medicine. 445 2007;120(8):713-719. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination 446 31. 447 antihypertensive medications, adherence, and clinical outcomes: a population-based 448 retrospective cohort study. PLoS medicine. 2018;15(6):e1002584. Ogedegbe G, Shah NR, Phillips C, et al. Comparative effectiveness of angiotensin-449 32. 450 converting enzyme inhibitor-based treatment on cardiovascular outcomes in hypertensive 451 blacks versus whites. Journal of the American College of Cardiology. 2015;66(11):1224-1233. Flack JM, Buhnerkempe MG. Race and antihypertensive drug therapy: edging closer to 452 33. 453 a new paradigm. Am Heart Assoc; 2022. p. 349-351. 454 34. Gu A, Yue Y, Desai RP, Argulian E. Racial and ethnic differences in antihypertensive 455 medication use and blood pressure control among US adults with hypertension: the National 456 Health and Nutrition Examination Survey, 2003 to 2012. Circulation: Cardiovascular Quality and 457 Outcomes. 2017;10(1):e003166. Derington CG, Cohen JB, Bress AP. Restoring the upward trend in blood pressure 458 35. 459 control rates in the United States: a focus on fixed-dose combinations. Journal of human hypertension. 2020;34(9):617-623. 460 Donohue JM, Cole ES, James CV, Jarlenski M, Michener JD, Roberts ET. The US 461 36. Medicaid program: coverage, financing, reforms, and implications for health equity. Jama. 462 463 2022;328(11):1085-1099. 464 37. Escobedo LE, Cervantes L, Havranek E. Barriers in healthcare for Latinx patients with limited English proficiency—a narrative review. Journal of general internal medicine. 465 466 2023;38(5):1264-1271.

- 467 38. King JB, Derington CG, Herrick JS, et al. Single-Pill Combination Product Availability of
  468 the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the
  469 Systolic Blood Pressure Intervention Trial. *Hypertension*. 2023;80(8):1749-1758.
- 470 39. Centers for Disease Control and Prevention. Fixed-Dose Combination Antihypertensive
- 471 Medications Coverage by State Medicaid and Medicaid Managed Care Organizations. Atlanta,
- 472 GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human
- 473 Services; 2022. Accessed May 22, 2024.
- 474 40. Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 475 ACC/AHA high blood pressure guideline. *Circulation*. 2018;137(2):109-118.
- 476 41. US Food & Drug. Hypertension: Developing Fixed-Dose Combination Drugs for
- 477 Treatment. Accessed May 31, 2024. https://www.fda.gov/regulatory-information/search-fda-
- 478 guidance-documents/hypertension-developing-fixed-dose-combination-drugs-treatment

479

It is made available under a CC-BY-NC 4.0 International license .

Table 1. Summary	<b>Statistics</b>	of Sample	Characteristics
------------------	-------------------	-----------	-----------------

	All	Combination-pill therapy	Multi-pill therapy	P- values
	N=325,600	N=29,328	N=296,272	
	(100%)	(9%)	(91%)	
Age, mean (SD)	49.3 (10.1)	48.2 (9.9)	49.4 (10.2)	< 0.001
Age groups, n (%)				
18-34	31,428 (9.65%)	2,884 (9.83%)	28,544 (9.63%)	0.27
35-44	67,531 (20.74%)	7,415 (25.28%)	60,116 (20.29%)	< 0.001
45-54	102,795 (31.57%)	9,537 (32.52%)	93,258 (31.48%)	< 0.001
55-64	123,846 (38.04%)	9,492 (32.36%)	114,354 (38.60%)	< 0.001
Female, n (%)	181,776 (55.83%)	18,802 (64.11%)	162,974 (55.01%)	< 0.001
Race categories, n (%)				
Non-Hispanic White	174,306 (53.53%)	14,527 (49.53%)	159,779 (53.93%)	< 0.001
Non-Hispanic Black	93,122 (28.60%)	9,712 (33.12%)	83,410 (28.15%)	< 0.001
Hispanic	13,736 (4.22%)	1,290 (4.40%)	12,446 (4.20%)	0.11
Other race groups	44,436 (13.65%)	3,799 (12.95%)	40,637 (13.72%)	< 0.001
Risk factors, n (%)				
Alcohol use	21,338 (6.55%)	867 (2.96%)	20,471 (6.91%)	< 0.001
Tobacco use	83,496 (25.64%)	5,160 (17.59%)	78,336 (26.44%)	< 0.001
Obesity	79,341 (24.37%)	6,273 (21.39%)	73,068 (24.66%)	< 0.001
Lipid disorders	103,085 (31.66%)	6,769 (23.08%)	96,316 (32.51%)	< 0.001
Comorbidities, n (%)				
Dementia	1,530 (0.47%)	49 (0.17%)	1,481 (0.50%)	< 0.001
Chronic pulmonary disease	71,344 (21.91%)	4,052 (13.82%)	67,292 (22.71%)	< 0.001
Rheumatic disease	6,811 (2.09%)	433 (1.48%)	6,378 (2.15%)	< 0.001
Peptic ulcer disease	2,353 (0.72%)	97 (0.33%)	2,256 (0.76%)	< 0.001
Mild liver disease	19,666 (6.04%)	734 (2.50%)	18,932 (6.39%)	< 0.001
Diabetes without chronic				
complication	102,364 (31.44%)	6,054 (20.64%)	96,310 (32.51%)	< 0.001
Diabetes with chronic				
complication	40,848 (12.55%)	1,452 (4.95%)	39,396 (13.30%)	< 0.001
Hemiplegia or paraplegia	4,729 (1.45%)	140 (0.48%)	4,589 (1.55%)	< 0.001
Any malignancy	10,139 (3.11%)	662 (2.26%)	9,477 (3.20%)	< 0.001
Moderate or severe liver				
disease	3,071 (0.94%)	26 (0.09%)	3,045 (1.03%)	< 0.001
Metastatic solid tumor	1,731 (0.53%)	96 (0.33%)	1,635 (0.55%)	< 0.001
AIDS/HIV	3,154 (0.97%)	242 (0.83%)	2,912 (0.98%)	0.009

Abbreviations:

<sup>a</sup> We employed the Wilcoxon nonparametric rank-sum test to examine differences in means across continuous variables, while Pearson's Chi-square test was utilized to assess variations in proportions across categorical variables based on combination-pill and multi-pill therapies.

It is made available under a CC-BY-NC 4.0 International license .

	All	NH White	NH Black	Hispanic				
Medication Adherence (MPR ≥ 80%) to Antihypertensives								
Multi-pill therapy <sup>b</sup>	0.395	0.444	0.309	0.386				
	(0.393 - 0.397)	(0.442 - 0.447)	(0.305 - 0.312)	(0.376 - 0.395)				
Combination-pill								
therapy only <sup>b</sup>	0.480	0.541	0.378	0.442				
	(0.474 - 0.485)	(0.534 - 0.549)	(0.368 - 0.387)	(0.416 - 0.469)				
Difference <sup>c</sup>	0.085***	0.097***	0.069***	0.057***				
	(0.079 - 0.091)	(0.089 - 0.105)	(0.059 - 0.079)	(0.029 - 0.085)				
Observations	325,600	174,306	93,122	13,736				
	Med	ication Possession R	atios	·				
Multi-pill therapy	65.66	69.23	59.27	66.33				
	(65.53 - 65.78)	(69.06 - 69.40)	(59.04 - 59.50)	(65.72 - 66.93)				
Combination-pill								
therapy only	68.83	73.11	61.03	69.94				
	(68.47 - 69.19)	(72.60 - 73.63)	(60.40 - 61.67)	(68.26 - 71.63)				
Difference	3.17***	3.88***	1.76***	3.62***				
	(2.79 - 3.55)	(3.34 - 4.42)	(1.09 - 2.44)	(1.83 - 5.40)				
Observations	325,600	174,306	93,122	13,736				

#### Table 2. The Association of Combination-Pill Therapy Use with Medication Adherence and Medication Possession Ratios (per individual)<sup>a</sup>

<sup>a</sup> Logistic regression was employed to analyze medication adherence, while linear regression was used for medication possession ratios. Average marginal effects, along with 95% confidence intervals, were reported. All models were adjusted for 12 Charlson comorbidities, risk factors (alcohol use, tobacco use, obesity, and lipid disorders), gender, age groups (aged 18-34, aged 35-44, aged 45-54, and aged 55-64), race/ethnicity, and fixed effects for the year and month of the index date.

<sup>b</sup> Those who used combination-pill therapy comprise individuals who exclusively used FDC-antihypertensives during the one-year follow-up periods from the antihypertensive index date. Those who used multi-pill therapy comprise individuals who did not use FDC-antihypertensives during the one-year follow-up periods.

<sup>c</sup> The reported differences reflect the predicted outcomes, specifically the average marginal effects, for individuals receiving combination-pill therapy compared with those receiving multi-pill therapy. \*\*\* P < 0.001, \*\* P < 0.01, \* P < 0.05

It is made available under a CC-BY-NC 4.0 International license .

Table 3. The Association of Combination-Pill Therapy Use with Hypertension- and
Cardiovascular Disease- Related Health Care Utilization (per 1,000 individuals) <sup>a</sup>

	ascular Disease- Related Health Care Othization (per 1,000 multitudias)							
	Num. HTN-	Num. HTN-related	Num. CVD-	Num. CVD-				
	related <sup>c</sup> ED	Inpatient	related <sup>d</sup> ED	related Inpatient				
	visits	Admissions	visits	Admissions				
All								
Multi-pill therapy <sup>b</sup>	697.7	227.5	768.1	261.2				
	(689.0 - 706.4)	(221.6 - 233.3)	(758.8 - 777.5)	(254.3 - 268.0)				
Combination-pill								
therapy only <sup>b</sup>	478.1	74.78	498.0	80.33				
	(465.0 - 491.2)	(70.91 - 78.65)	(484.6 - 511.4)	(76.23 - 84.43)				
Difference <sup>c</sup>	-219.6***	-152.7***	-270.1***	-180.9***				
	(-235.4203.8)	(-159.8145.6)	(-286.5253.8)	(-188.8172.9)				
Observations	325,600	325,600	325,600	325,600				
Non-Hispanic White	,	,	,	,				
Multi-pill therapy	589.4	207.4	662.5	246.3				
1	(579.9 - 599.0)	(201.2 - 213.6)	(652.2 - 672.9)	(238.9 - 253.7)				
Combination-pill			, , , , , , , , , , , , , , , , , , , ,	,,				
therapy only	417.5	73.64	437.9	79.27				
	(400.3 - 434.7)	(67.97 - 79.31)	(420.3 - 455.6)	(73.28 - 85.26)				
Difference	-171.9***	-133.8***	-224.6***	-167.0***				
	(-192.0151.8)	(-142.2125.4)	(-245.5203.8)	(-176.6157.5)				
Observations	174,306	174,306	174,306	174,306				
Non-Hispanic Black		,	,	,				
Multi-pill therapy	898.1	270.5	969.5	299.6				
1 17	(882.0 - 914.1)	(261.2 - 279.8)	(952.6 - 986.5)	(289.2 - 310.0)				
Combination-pill				, ,				
therapy only	610.8	78.38	633.0	84.55				
1,5 5	(584.3 - 637.4)	(71.01 - 85.74)	(605.9 - 660.0)	(76.72 - 92.37)				
Difference	-287.2***	-192.1***	-336.6***	-215.0***				
	(-318.0256.4)	(-204.0180.2)	(-368.3304.9)	(-227.9202.1)				
Observations	93,122	93,122	93,122	93,122				
Hispanic	7	)		,				
Multi-pill therapy	512.9	142.8	566.9	164.4				
	(488.2 - 537.6)	(131.8 - 153.8)	(540.7 - 593.1)	(152.2 - 176.6)				
Combination-pill	(10012 00110)	()		(				
therapy only	390.3	54.48	402.7	55.87				
1.7 .7	(324.2 - 456.5)	(37.93 - 71.03)	(334.6 - 470.8)	(39.01 - 72.74)				
Difference	-122.6***	-88.3***	-164.2***	-108.5***				
	(-192.452.8)	(-108.568.2)	(-236.392.2)	(-129.687.5)				
Observations	13,736	13,736	13,736	13,736				

<sup>a</sup> A negative binomial model was used for all count variables. Average marginal effects, along with 95% confidence intervals, were reported. All models were adjusted for 12 Charlson comorbidities, risk factors (alcohol use, tobacco use, obesity, and lipid disorders), gender, age groups (aged 18-34, aged 35-44, aged 45-54, and aged 55-64), race/ethnicity and fixed effects for the year and month of the index date.

<sup>b</sup> Those who used combination-pill therapy comprise individuals who exclusively used FDC-antihypertensive during the one-year follow-up periods from the antihypertensive index date. Those who used multi-pill therapy comprise those who did not use FDC-antihypertensive during the one-year follow-up periods.

<sup>c</sup> The reported differences reflect the predicted outcomes, specifically the average marginal effects, for individuals receiving combination-pill therapy compared with those receiving multi-pill therapy.

<sup>d</sup> Hypertension (HTN)-related emergency department (ED) visits and inpatient admissions are defined as those containing an HTN diagnosis (ICD-10-CM codes I10–I15). Cardiovascular disease (CVD)-related ED visits and inpatient admissions are defined as those containing a CVD diagnosis (ICD-10-CM codes I00–I78). \*\*\* P<0.001, \*\* P<0.01, \* P<0.05

	HTN-related total medical costs, \$	HTN-related ED costs, \$	HTN-related inpatient costs, \$	CVD-related total medical costs, \$	CVD-related ED costs, \$	CVD-related inpatient costs, \$
All						
Multi-pill therapy <sup>b</sup>	4,842	470	3,067	5,976	520.8	3,680
	(4,717 - 4,968)	(450.9 - 489.9)	(2,897 - 3,237)	(5,821 - 6,130)	(499.8 - 541.9)	(3,466 - 3,893)
Combination-pill						
therapy only <sup>b</sup>	1,980	245	787	2,196	252	882
	(1,858 - 2,102)	(228 - 263)	(696 - 878)	(2,064 - 2,329)	(235 - 270)	(781 - 982)
Difference <sup>c</sup>	-2,862***	-225***	-2,280***	-3,779***	-269***	-2,798***
	(-3,0352,689)	(-251 – -199)	(-2,4642,096)	(-3,9783,581)	(-295 – -242)	(-3,0182,578)
Observations	128,528	128,528	128,528	128,528	128,528	128,528
Non-Hispanic White						
Multi-pill therapy	3,900	379	2,604	4,976	436	3,264
	(3,765 - 4,034)	(360.2 - 397.2)	(2,422 - 2,785)	(4,809 - 5,144)	(416 - 457)	(3,035 - 3,492)
Combination-pill						
therapy only	1,774	208	855	1,964	216	969
	(1,603 - 1,944)	(185 - 232)	(705 - 1,005)	(1,781 - 2,147)	(192 - 240)	(804 - 1,134)
Difference	-2,126***	-171***	-1,749***	-3,012***	-220***	-2,294***
	(-2,3391,912)	(-200 – -141)	(-1,9721,526)	(-3,2552,769)	(-252 – -189)	(-2,5592,030)
Observations	60,139	60,139	60,139	60,139	60,139	60,139
Non-Hispanic Black						
Multi-pill therapy	6,235	625	3,606	7,498	679	4,202
	(5,996 - 6,474)	(593 - 657)	(3,336 - 3,876)	(7,214 - 7,783)	(645 - 713)	(3,877 - 4,527)
Combination-pill therapy only	2,339	327	693	2,584	335	783
	(2,152 - 2,526)	(293 - 360)	(575 - 811)	(2,378 - 2,790)	(302 - 369)	(649 - 916)
Difference	-3,896***	-299***	-2,913***	-4,914***	-344***	-3,419***
	(-4,1983,595)	(-344253)	(-3,2102,616)	(-5,2584,571)	(-391297)	(-3,7643,074)
Observations	39,326	39,326	39,326	39,326	39,326	39,326
Hispanic						
Multi-pill therapy	2,035	107	1,605	2,563	118	1,964
	(1,827 - 2,244)	(80 - 135)	(1,372 - 1,837)	(2,300 - 2,827)	(90 - 146)	(1,683 - 2,245)

## Table 4. The Association of Combination-Pill Therapy Use with Medical Costs Associated with Hypertension and Cardiovascular Disease (CVD) (per individual)<sup>a</sup>

Combination-pill						
therapy only	776.4	43	423	837	45	447
	(531.4 - 1,021)	(25 - 61)	(210 - 636)	(583 - 1,091)	(27 - 63)	(229 - 665)
Difference	-1,259***	-64***	-1,181***	-1,727***	-73***	-1,517***
	(-1,584934)	(-97 – -32)	(-1,502861)	(-2,0951,359)	(-106 – -40)	(-1,8761,159)
Observations	8,690	8,690	8,690	8,690	8,690	8,690


<sup>a</sup> Hypertension-related and CVD-related healthcare utilization and total medical costs were defined based on the presence of respective diagnosis codes (hypertension: ICD-10-CM codes I10-I15; CVD: ICD-10-CM codes I00-I78). A generalized linear model with a gamma distribution and log link was used for all cost outcomes. Average marginal effects, along with 95% confidence intervals, were reported. All models were adjusted for 12 Charlson comorbidities, risk factors (alcohol use, tobacco use, obesity, and lipid disorders), gender, age groups (aged 18-34, aged 35-44, aged 45-54, and aged 55-64), race/ethnicity, and fixed effects for the year and month of the index date.


<sup>b</sup> Those who used combination-pill therapy comprise individuals who exclusively used FDC-antihypertensives during the one-year follow-up periods from the antihypertensive index date. Those who used multi-pill therapy comprise those who did not use FDC-antihypertensive during the one-year follow-up periods.

<sup>c</sup> The reported differences reflect the predicted outcomes, specifically the average marginal effects, for individuals receiving combination-pill therapy compared with those receiving multi-pill therapy.

\*\*\* P<0.001, \*\* P<0.01, \* P<0.05

It is made available under a CC-BY-NC 4.0 International license .





<sup>a</sup> Those who used combination-pill therapy comprise individuals who exclusively used FDC-antihypertensives during the one-year follow-up periods from the antihypertensive index date. Those who used multi-bill therapy comprise those who did not use FDC-antihypertensives during the one-year follow-up periods.